Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma

被引：2
|
作者：
Thompson, J. A.
Berman, D.
Siegal, J.
Minor, D.
Amin, A.
Ron, I.
Ridolfi, R.
Assi, H.
Hamid, O.
Weber, J.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Bristol Myers Squibb, Bristol, Avon, England
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.9055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9055
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] COMPARISON OF HEALTHCARE COSTS IN FRANCE OF COMBINATION NIVOLUMAB AND IPILIMUMAB TREATMENT VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Bregman, B.
    Moshyk, A.
    Johnson, H. M.
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [43] INDIRECT COMPARISON OF PEMBROLIZUMAB TO VEMURAFENIB AND DABRAFENIB MONOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BRAF MUTATION POSITIVE IPILIMUMAB NAIVE PATIENTS
    Jansen, J. P.
    Stevinson, K.
    Wang, J.
    VALUE IN HEALTH, 2016, 19 (03) : A138 - A138
  • [44] Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
    Maio, Michele
    Grob, Jean-Jacques
    Aamdal, Steinar
    Bondarenko, Igor
    Robert, Caroline
    Thomas, Luc
    Garbe, Claus
    Chiarion-Sileni, Vanna
    Testori, Alessandro
    Chen, Tai-Tsang
    Tschaika, Marina
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1191 - 1196
  • [45] Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases
    Margolin, K.
    Hodi, F. S.
    McDermott, D. F.
    Lawrence, D. P.
    Hamid, O.
    Puzanov, I.
    Thompson, J. A.
    Ernstoff, M. S.
    Michener, T. L.
    Heller, K. N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S654 - S654
  • [46] Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
    Maio, M.
    Danielli, R.
    Chiarion-Sileni, V.
    Pigozzo, J.
    Parmiani, G.
    Ridolfi, R.
    De Rosa, F.
    Del Vecchio, M.
    Di Guardo, L.
    Queirolo, P.
    Picasso, V.
    Marchetti, P.
    De Galitiis, F.
    Mandala, M.
    Guida, M.
    Simeone, E.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2911 - 2915
  • [47] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [48] Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
    O'Day, S. J.
    Maio, M.
    Chiarion-Sileni, V.
    Gajewski, T. F.
    Pehamberger, H.
    Bondarenko, I. N.
    Queirolo, P.
    Lundgren, L.
    Mikhailov, S.
    Roman, L.
    Verschraegen, C.
    Humphrey, R.
    Ibrahim, R.
    de Pril, V.
    Hoos, A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1712 - 1717
  • [49] CHECKMATE 066: EFFECT OF NIVOLUMAB (NIVO) ON QUALITY OF LIFE (QoL) IN PATIENTS (pts) WITH TREATMENT-NAIVE ADVANCED MELANOMA (MEL)
    Long, G. V.
    Atkinson, V.
    Ascierto, P. A.
    Robert, C.
    Hassel, J. C.
    Rutkowski, P.
    Savage, K. J.
    Taylor, F.
    Coon, C.
    Gilloteau, I.
    Dastani, H. B.
    Waxman, I.
    Abernethy, A. P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 58 - 58
  • [50] EFFECT AND TOLERABILITY OF AGALSIDASE ALFA WERE ASSESSED IN PATIENTS WITH FABRY DISEASE WHO WERE TREATMENT-NAIVE (NAIVE) OR PREVIOUSLY TREATED WITH AGALSIDASE BETA (SWITCH PATIENTS)
    Goker-Alpan, Ozlem
    Ibrahim, Jennifer
    Nedd, Khan
    Shankar, Suma
    Lein, Howard
    Barshop, Bruce
    Boyd, Ellen
    Holida, Myrl
    Hillman, Richard
    Ibrahim, Jennifer
    Mardach, Rebecca
    Wienreb, Neil
    Rever, Barbara
    Forte, Richard
    Desai, Alpana
    Wijatyk, Anna
    Chang, Peter
    Martin, Rick
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 316 - 316
12345